前列腺癌患者骨摄取:PSMA-RADS v1.0、临床、生物学及68Ga-PSMA-11 PET特征预测生化复发后转移的诊断效能
多中心回顾性队列纳入298例局部治疗后生化复发的前列腺癌患者,98例(32.9%)在PSMA PET/CT上显示骨摄取,最终诊断的81个病灶中28个(34.6%)为转移。PSMA-RADS-4或5诊断转移的敏感度79%、特异度94%、准确率89%,PSMA-RADS的AUC显著高于临床实践初始判读(0.91 vs 0.83,P=0.0074)。
要点
- PSMA PET/CT上多数骨摄取为良性病变,最终诊断病灶中仅34.6%为转移。
- PSMA-RADS-4或5诊断骨转移敏感度79%、特异度94%、准确率89%。
- 初始Gleason评分≥8、复发时年龄≤71岁、SUVmax>6.21为转移的独立预测因素。
核心结论
- PSMA PET/CT上大多数骨摄取为良性病变,PSMA-RADS、患者及肿瘤特征和SUVmax有助于识别前列腺癌骨转移。
研究设计与样本
- 多中心回顾性队列,连续纳入局部治疗后生化复发的前列腺癌患者,分析临床、生物学及影像特征。
- 由两名核医学医师评估PSMA-RADS、解剖位置、影像模式、SUVmax及其他分子病灶。
- 采用单因素和多因素分析寻找前列腺癌转移的独立预测因素。
主要发现
- 可评估人群中98/298例(32.9%)PSMA PET/CT显示骨摄取。
- 在有最终诊断的患者中,28/81个病灶(34.6%)为转移。
- PSMA-RADS-4或5诊断转移的敏感度79%、特异度94%、准确率89%。
- PSMA-RADS的ROC曲线下面积显著高于临床实践初始判读(0.91 vs 0.83,P=0.0074)。
- 多因素logistic回归显示初始Gleason评分≥8、复发时年龄≤71岁、SUVmax>6.21为前列腺癌转移的独立预测因素(P分别为0.0314、0.0179、0.0003)。
关键数值与推荐
- PSMA-RADS-4或5:敏感度79%、特异度94%、准确率89%。
- PSMA-RADS的AUC为0.91,临床实践初始判读为0.83(P=0.0074)。
- 初始Gleason评分≥8、复发时年龄≤71岁、SUVmax>6.21为独立预测因素(P=0.0314、0.0179、0.0003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 68 Gallium-labeled prostate-specific membrane antigen-11 (PSMA) PET/CT is the new reference to identify relapse during biochemical recurrence of prostate cancer (PCa). However, this method lacks specificity for bone foci. This study aimed to report the prevalence of PCa bone metastases and to assess the diagnostic performances of PSMA reporting and data systems (RADS), clinical, biological, and imaging features for identification. PATIENTS AND METHODS: A multicentric retrospective cohort of consecutive patients with biochemical recurrence after local treatment was analyzed. Clinical and biological features at initial staging and during recurrence were retrieved from medical reports. The metastatic status of each bone uptake on PSMA PET/CT was determined according to histopathology, comparisons with concomitant and previous conventional imaging, prostate-specific antigen kinetic, and follow-up. Two nuclear medicine physicians assessed PSMA-RADS, anatomic location, radiological patterns, SUV max , and the presence of other molecular lesions. Univariate and multivariate analyses were conducted to identify independent predictors of PCa metastases. RESULTS: In the eligible population, 98/298 patients (32.9%) showed bone uptake on PSMA PET/CT. In patients with a final diagnosis, 28/81 lesions (34.6%) were metastases. PSMA-RADS-4 or 5 showed sensitivity of 79%, specificity of 94%, and accuracy of 89%. PSMA-RADS had a significantly higher area under the receiver operating characteristic curve than the initial reading in clinical practice (0.91 vs 0.83, P = 0.0074). Initial Gleason score ≥8, age ≤71 years at recurrence, and SUV max >6.21 were independent predictors of PCa metastases in multivariate logistic regression ( P = 0.0314, 0.0179, and 0.0003, respectively). CONCLUSIONS: Most bone uptakes at PSMA PET/CT were benign lesions. PSMA-RADS, patients and tumor characteristics, and SUV max could help identify PCa bone metastases.
引用
- Letang A, Crombé A, Rousseau C, et al. Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68 Ga-PSMA-11 PET Features to Predict Metastasis After Biochemical Recurrence. Clin Nucl Med. 2022. PMID: 35543633. doi:10.1097/RLU.0000000000004259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。